J. Mater. Sci. Technol. ›› 2023, Vol. 151: 150-161.DOI: 10.1016/j.jmst.2022.12.032

• Research Article • Previous Articles     Next Articles

Nickel phosphide for MRI-guided synergistic photo-immunotherapy

Na Ana, Yan Gaoa, Ying Shib, Xingxing Duc, Jianing Chengc, Shuanglong Tanga, Pengfei Liub, Huike Yangc,*, Chongshen Guoa,*   

  1. aSchool of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, 150001, China;
    bMagnetic Resonance Department of the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China;
    cDepartment of Anatomy, Harbin Medical University, Harbin, 150081, China
  • Received:2022-09-06 Revised:2022-11-21 Accepted:2022-12-05 Published:2023-07-10 Online:2023-02-16
  • Contact: * E-mail addresses: huikeyang@hrbmu.edu.cn (H. Yang), chongshenguo@hit.edu.cn(C. Guo).

Abstract: Developing a phototherapy modality to ablate tumor and then trigger immunogenic cell death (ICD) for simultaneously eliminating distal and metastatic tumors holds great promise in clinical applications. Herein, the polyethylene glycol functionalized Ni2P (Ni2P@PEG NPs) is developed with enhanced biocompatibility, high photoabsorption and photothermal efficiency, as well as reactive oxygen species generation ability. Of particular note, Ni2P@PEG NPs mediated phototherapy could not only realize efficient ablation of primary tumors, but also inhibit distal tumors and metastatic tumors by triggering an antitumor immune response. The above conclusions were verified by B mode ultrasound, western blot assay, and immunohistochemistry analysis. Meanwhile, Ni2P@PEG NPs showed excellent magnetic resonance imaging (MRI) properties. In summary, the MRI-guided multimodal cancer therapies of Ni2P@PEG NPs represent significant potential for clinical applications.

Key words: Nickel phosphide, Magnetic resonance imaging, Phototherapy, Immunotherapy